Not Signed In -
Linezolid Oral Suspension |
Zyvox Suspension |
Clinical Trial: Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
This study is currently recruiting patients.
Verified by Pfizer September 2005
|
Purpose
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
| Condition | Intervention | Phase |
|---|---|---|
| Staphylococcus aureus Methicillin resistance | Drug: linezolid | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-Label, Multi-Center Trial
Further Study Details:
Primary Outcomes: Resolution of infection at the time of completion of therapy
Secondary Outcomes: Adverse events
Expected Total Enrollment: 20
Secondary Outcomes: Adverse events
Expected Total Enrollment: 20
Study start: January 2003
Eligibility
Ages Eligible for Study: 16 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- infection due to methicillin-resistant Staphylococcus aureus
Exclusion Criteria:
- hypersensitivity to linezolid
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00150332
Toshide Ito 81-3-5039-7449 toshide.ito@pfizer.com
Japan
Pfizer Investigational Site, Fukuoka, 813-0025, Japan; Recruiting
Pfizer Investigational Site, Fukuoka, 811-0213, Japan; Recruiting
Pfizer Investigational Site, Nagasaki, 852-8501, Japan; Recruiting
Pfizer Investigational Site, Okayama, 700-8505, Japan; Completed
Pfizer Investigational Site, Okayama, 703-8275, Japan; Recruiting
Japan, Chiba
Pfizer Investigational Site, Kamogawa, Chiba, 296-0041, Japan; Recruiting
Japan, Fukuoka
Pfizer Investigational Site, Onga-gun, Fukuoka, 807-0051, Japan; Recruiting
Japan, Hokkaido
Pfizer Investigational Site, Sapporo, Hokkaido, 006-8555, Japan; Completed
Pfizer Investigational Site, Sappopro, Hokkaido, 060-8648, Japan; Completed
Japan, Ibaraki
Pfizer Investigational Site, Moriya, Ibaraki, 302-0118, Japan; Recruiting
Japan, Nagasaki
Pfizer Investigational Site, Isahaya, Nagasaki, 854-8501, Japan; Recruiting
Japan, Okayama
Pfizer Investigational Site, Kurashiki, Okayama, 701-0912, Japan; Recruiting
Japan, Osaka
Pfizer Investigational Site, Suita, Osaka, 565-8565, Japan; Recruiting
Japan, Saitama
Pfizer Investigational Site, Iruma-gun, Saitama, 350-0495, Japan; Recruiting
Japan, TOKYO
Pfizer Investigational Site, Kodaira-shi, TOKYO, 187-0004, Japan; Recruiting
Study chairs or principal investigators
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Study ID Numbers: M12600067
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00150332
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00150332
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Linezolid Oral Suspension (Drug Digest)
- Zyvox Suspension (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
